performance-based pricing

As CAR-T launch ramps up in U.S., Novartis' Narasimhan looks to convince Japan on performance-based pricing
Fierce Pharma
Thu, 10/5/17 - 06:16 pm
Novartis
CAR-T
Vas Narasimhan
Japan
drug pricing
performance-based pricing